Trials / Completed
CompletedNCT00876083
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
Post-marketing Surveillance Study Ultravist®-IMAGE IoproMide (UltrAvist®) to Gain Further Information on Tolerability and Safety in X-ray Examination
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44,920 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study. No other examinations will be performed than would have been done routinely.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ultravist (Iopromide, BAY86-4877) | Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist. |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-04-06
- Last updated
- 2011-02-28
Locations
21 sites across 21 countries: Bosnia and Herzegovina, China, Germany, Hungary, Indonesia, Iran, Italy, Malaysia, Moldova, Pakistan, Philippines, Poland, Romania, Russia, Saudi Arabia, Singapore, South Korea, Taiwan, Thailand, Ukraine, Vietnam
Source: ClinicalTrials.gov record NCT00876083. Inclusion in this directory is not an endorsement.